UNSPSC 51102843: Dexamethasone/neomycin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102843 Dexamethasone/neomycin is a Commodity code that nominally identifies a specific pharmaceutical combination, but recent state and local opportunities tagged under it show substantial scope mismatch — solicitations are predominantly for broader pharmaceutical procurement categories, emergency medical supplies, and pharmacy program infrastructure rather than this specific formulation. The code sees activity across health departments, fire rescue divisions, and cooperative purchasing vehicles, reflecting state and local government's need to source medications and medical supplies through competitive bidding, RFPs, and multi-state cooperative arrangements. Work actually being procured includes generic pharmaceuticals and OTC products through wholesaler networks, emergency response medical supplies for fire and rescue operations, and direct-to-manufacturer pharmacy program design.

Recent activity spans Florida, Texas, Minnesota, and participating states in multi-state cooperatives. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for community health initiatives with quarterly deliveries. The City of Tampa's Purchasing Department issued an IFB (26P00145, due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000 and designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Department of Administration issued an RFP through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026), requiring distribution through three authorized wholesalers and effective July 1, 2026. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program as preliminary market intelligence before issuing a formal RFP.